/PCVX
PCVX Stock - Vaxcyte, Inc.
Healthcare|BiotechnologyNASDAQ
$46.42+6.20%
+$2.71 (+6.20%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+65.9%upside
Target: $77.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PCVX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$45.96 – $46.88
TARGET (TP)$77.00
STOP LOSS$42.71
RISK/REWARD1:8.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.28
52W High$93.77
52W Low$27.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-1,405,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-569,546,000 | $-468,041,000 | $-232,256,000 | $-103,670,000 | $-89,581,000 |
| Net Income | $-463,927,000 | $-402,266,000 | $-223,485,000 | $-100,077,000 | $-89,217,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-2.97 |
Company Overview
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
86%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$73
Average Target
↑ 56.2% Upside
Now
$38
Low
$73
Average
$135
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 12th 2025 | Goldman | Initiation | Neutral | $38 |
| April 22nd 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| December 20th 2024 | Goldman | Initiation | Buy | $135 |
| December 7th 2023 | Mizuho | Initiation | Buy | $69 |
| April 18th 2023 | TD Cowen | Initiation | Outperform | - |
| January 3rd 2023 | Needham | Reiterated | Buy | $58← $52 |
| December 15th 2022 | Guggenheim | Initiation | Buy | $66 |
| November 17th 2022 | BTIG Research | Initiation | Buy | $69 |
Earnings History & Surprises
PCVXBeat Rate
28%
Last 18 quarters
Avg Surprise
-8.9%
EPS vs Estimate
Beats / Misses
5/12
1 met exactly
Latest EPS
$-1.56
Q4 2025
EPS Surprise History
Q1 24
-102.2%
$-1.82vs$-0.90
Q2 24
+24.8%
$-0.85vs$-1.13
Q3 24
-12.8%
$-1.10vs$-0.98
Q4 24
+24.5%
$-0.83vs$-1.10
Q1 25
+12.1%
$-1.02vs$-1.16
Q2 25
-2.0%
$-1.04vs$-1.02
Q3 25
-8.9%
$-1.22vs$-1.12
Q4 25
-22.8%
$-1.56vs$-1.27
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-1.46 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-1.27 | $-1.56 | -22.8% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-1.12 | $-1.22 | -8.9% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-1.02 | $-1.04 | -2.0% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-1.16 | $-1.02 | +12.1% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-1.10 | $-0.83 | +24.5% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.98 | $-1.10 | -12.8% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-1.13 | $-0.85 | +24.8% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.90 | $-1.82 | -102.2% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.79 | $-0.91 | -15.2% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.67 | $-0.70 | -4.5% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.80 | $-0.70 | +12.5% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.84 | $-0.73 | +13.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.80 | $-0.93 | -16.3% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.69 | $-0.80 | -15.9% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.56 | $-0.68 | -21.4% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.46 | $-0.54 | -17.4% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.47 | $-0.51 | -8.5% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.46 | $-0.46 | 0.0% | = MET |
Latest News
Vaxcyte Announces First Participants Dosed In OPUS Phase 3 Pivotal, Noninferiority Trial Evaluating VAX-31 For Prevention Of Invasive Pneumococcal Disease And Pneumonia In Adults
📈 PositiveBenzinga•Dec 8, 2025, 12:10 PM
BTIG Reiterates Buy on Vaxcyte, Maintains $85 Price Target
📈 PositiveBenzinga•Nov 10, 2025, 10:31 AM
Vaxcyte Q3 EPS $(1.56) Misses $(1.30) Estimate
📉 NegativeBenzinga•Nov 4, 2025, 09:47 PM
Vaxcyte Enters Partnership With Thermo Fisher Scientific To Secure Additional U.S. Fill-Finish Commercial Manufacturing For Its Broad-Spectrum Pneumococcal Conjugate Vaccines Representing Up To $1B in Manufacturing And Service
📈 PositiveBenzinga•Sep 30, 2025, 12:44 PM•Also:
Goldman Sachs Initiates Coverage On Vaxcyte with Neutral Rating, Announces Price Target of $38
➖ NeutralBenzinga•Sep 12, 2025, 03:32 PM
Vaxcyte Advances Study of New Vaccine for Pneumococcal Disease in Infants, Pegtibatinase Maintained Significant Reductions in Toxic Metabolites
📈 PositiveBenzinga•Sep 3, 2025, 11:33 AM
Shares of vaccine companies are trading lower following a Daily Beast report suggesting that President Trump and Health and Human Services Robert F. Kennedy, Jr. will ban Covid-19 vaccines "within months.
📉 NegativeBenzinga•Aug 25, 2025, 05:50 PM•Also: , ,
Frequently Asked Questions about PCVX
What is PCVX's current stock price?
Vaxcyte, Inc. (PCVX) is currently trading at $46.42 per share. The stock has moved +6.20% today.
What is the analyst price target for PCVX?
The average analyst price target for PCVX is $77.00, based on 1 analyst.
What sector is Vaxcyte, Inc. in?
Vaxcyte, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PCVX's market cap?
Vaxcyte, Inc. has a market capitalization of $6.08 billion, making it a mid-cap company.
Does PCVX pay dividends?
No, Vaxcyte, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
ALKS
Alkermes plc
$28.45
Mkt Cap: $4.7B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
CRNX
Crinetics Pharmaceuticals, Inc.
$48.01
Mkt Cap: $4.6B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
KRYS
Krystal Biotech, Inc.
$240.80
Mkt Cap: $7.0B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
PTCT
PTC Therapeutics, Inc.
$78.57
Mkt Cap: $6.3B
TGTX
TG Therapeutics, Inc.
$30.98
Mkt Cap: $4.9B
Explore stocks similar to PCVX for comparison